Some molecules are famous for one dramatic job. NAD+ is famous for being everywhere. Nicotinamide adenine dinucleotide is a coenzyme that cells cannot run without — it shuttles the electrons that energy production depends on, and it is the raw material for a set of enzymes that repair DNA and tune metabolism. When researchers noticed that NAD+ appears to decline with age, the implication was hard to ignore: if the molecule everything runs on is running low, topping it back up might touch many of aging’s problems at once. That idea has become one of longevity science’s biggest stories — and one of its best lessons in the gap between a beautiful hypothesis and a proven therapy.
What NAD+ actually does
Two roles make NAD+ central. First, it is one of the cell’s central electron carriers. In the reactions that extract energy from food, NAD+ accepts electrons (becoming NADH) and delivers them to the mitochondrial electron transport chain, where that cargo ultimately drives ATP production. When the NAD+/NADH balance is disrupted, that redox bookkeeping falters and cellular energy metabolism is impaired.
Second, NAD+ is consumed — not just recycled — as a substrate by several important enzyme families. The sirtuins, a group of proteins tied to metabolic regulation and stress resistance, use NAD+ to do their work. So do the PARPs, which respond to DNA damage, and CD38, an enzyme whose activity tends to rise with age. Because these enzymes burn through NAD+, the cell must continually resynthesize it. This dual identity — indispensable cofactor and consumable substrate — is exactly why NAD+ levels are dynamic, and why they might drift downward over a lifetime.
The decline, and an honest caveat
The premise driving the field is that NAD+ falls with age, and a substantial body of work — much of it in animal tissue and cell models — supports that picture, tying lower NAD+ to reduced mitochondrial function and diminished repair capacity. It is a genuinely compelling story, and the biology underneath it is real.
It is also worth stating precisely: a clear, consistent age-related decline of NAD+ in humans has been demonstrated in only a limited number of studies, and measurements vary by tissue and method. The decline is well supported in principle and still being pinned down in people — a distinction that matters, because the case for supplementation rests on it.
Raising NAD+: the part that works
Here the news is encouraging and clear. Rather than trying to dose NAD+ directly, most human intervention research has focused on precursors the body converts into it — chiefly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). And these do engage the biochemistry: human studies generally show increases in circulating NAD-related metabolites after supplementation, though the magnitude of the rise and the response in different tissues vary from study to study. In one placebo-controlled study, aged men given NR showed a measurably elevated muscle NAD+ metabolome along with a dampening of circulating inflammatory signals. Across trials NR and NMN have generally appeared well tolerated over the durations studied, though the biochemical response varies by precursor, dose, population, and tissue.
So the first link in the chain looks solid: precursors can engage the NAD+ pathway in people. That is not a small thing — it means the intervention alters or engages the intended biochemical pathway in humans, which is more than many longevity ideas can claim.
Where the evidence is still open
The harder question is what that increase does for health and aging, and here the honesty of the field is its strength. Despite powerful preclinical results — in mice, restoring NAD+ can improve metabolism, endurance, and markers of tissue health — human trials to date have generally shown limited or inconsistent clinical benefit on hard functional outcomes. Engaging the NAD+ pathway in people is achievable; translating that into measurably better strength, metabolic health, or healthspan is not yet.
A 2025 review in Nature Metabolism frames this well, laying out both the clinical evidence and the open challenges: questions of optimal dose, which tissues actually take up the precursors, which populations stand to benefit, and which endpoints truly capture an effect. None of this makes the biology less interesting. It means NAD+ is exactly where the most valuable science happens — past the point of a promising idea, into the demanding work of finding out whether and how it helps.
Why it matters
NAD+ is the clearest case study in modern longevity research: a mechanism deep enough to plausibly touch many facets of aging, a precursor strategy that can measurably engage its intended biochemical pathway, and a set of human trials still working to show downstream benefit. Following it teaches the whole discipline in miniature — that engaging a mechanism and improving an outcome are different milestones, and that the distance between them is where the real discovery lives. That the biology is this rich, and the questions this concrete, is what makes NAD+ one of the most rewarding threads in the field to watch.